S&P TSX Capped Composite...

US Dollar vs CAD

Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.

ANIX Anixa Biosciences Inc

2.75

0.00 (0.00%)

Pre Market

Last Updated: 03:09:58

Delayed by 15 minutes

Form SCHEDULE 13D/A - General Statement of Acquisition of Beneficial Ownership: [Amend]

Anixa Biosciences (NASDAQ:ANIX)
Historical Stock Chart
From Mar 2025 to Apr 2025

Click Here for more Anixa Biosciences Charts.

Anixa Biosciences (NASDAQ:ANIX)
Historical Stock Chart
From Apr 2024 to Apr 2025

Click Here for more Anixa Biosciences Charts.

Anixa Biosciences Inc News

Anixa Biosciences Receives Notice of Allowance from U.S. Patent and Trademark Office for CAR-T Technology, Further Strengthening its Robust Intellectual Property Portfolio
Monday 14 April 2025 (2 weeks ago) • PR Newswire (US)

Anixa Biosciences Receives Notice of Allowance from U.S. Patent and Trademark Office for Patent Covering Breast Cancer Vaccine Technology
Wednesday 9 April 2025 (3 weeks ago) • PR Newswire (US)

Anixa Biosciences to Present at the Jones Las Vegas Healthcare and Technology Innovation Conference on April 9th
Tuesday 1 April 2025 (4 weeks ago) • PR Newswire (US)

Anixa Biosciences Enters Letter of Intent with VERDI Solutions to Develop Artificial Intelligence-Guided Personalized and Off-the-Shelf Cancer Vaccines
Tuesday 25 March 2025 (1 month ago) • PR Newswire (US)

Anixa Biosciences Receives Notice of Allowance from USPTO for Ovarian Cancer Vaccine
Monday 24 March 2025 (1 month ago) • PR Newswire (US)

Form 8-K - Current report
Friday 21 March 2025 (1 month ago) • Edgar (US Regulatory)

Anixa Biosciences CEO to Present at the 2025 CAGLA NeauxCancer Conference on March 28th
Monday 17 March 2025 (1 month ago) • PR Newswire (US)

Form 10-Q - Quarterly report [Sections 13 or 15(d)]
Tuesday 11 March 2025 (2 months ago) • Edgar (US Regulatory)

Anixa Biosciences 2025 Annual Meeting of Stockholders to Include Investor Presentation Open to All Interested Parties
Monday 10 March 2025 (2 months ago) • PR Newswire (US)

Anixa Biosciences Announces Chief Development Officer Dr. Pam Garzone to Speak at the Alliance for Cancer Gene Therapy Summit 2025 on March 19th
Monday 3 March 2025 (2 months ago) • PR Newswire (US)

Anixa Biosciences and Moffitt Cancer Center Complete Dosing in Third Cohort in Ovarian Cancer CAR-T Clinical Trial
Wednesday 26 February 2025 (2 months ago) • PR Newswire (US)

Anixa Biosciences' Breast Cancer Vaccine was Featured on Fox News' "America Reports"
Tuesday 25 February 2025 (2 months ago) • PR Newswire (US)

More Anixa Biosciences Inc News Articles

Societe Generale Effekten

Societe Generale Effekten

Otf Europe Balanced

Societe Generale Effekten

ETF Fund Assets Class Q2...

Vontobel Financial Produ...

Vontobel Financial Produ...

Vontobel Financial Produ...

Societe Generale Effekten

Societe Generale Effekten

Societe Generale Effekten

Intesa Sanpaolo

Delayed Upgrade Clock

Support: +44 (0) 203 8794 460 | support@advfn.com

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions